The LAG-3/MHCII Blockade Bioassay is a bioluminescent cell-based assay that measures potency and stability of antibodies and other biologics designed to block the interaction of LAG-3 with its best characterized ligand, major histocompatibility complex II (MHCII). LAG-3, also known as CD223, is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells. LAG-3 plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of LAG-3 by MHCII inhibits TCR signaling, cytokine production and proliferation of activated T cells. Therapeutic antibodies designed to block the LAG-3/MHCII interaction show promising results in clinical trials for the treatment of a variety of cancers.
The LAG-3/MHCII Blockade Bioassay reflects the mechanism of action (MOA) of biologics designed to block the interaction of LAG-3 with its ligand, MHCII.
The Control Ab, Anti-LAG-3 is a mouse anti-human LAG-3 antibody that shows blocking activity for LAG-3 with its ligand MHCII. It is intended for use as a control with the LAG-3/MHCII Blockade Bioassay, which can be used to measure the potency and stability of antibodies and other biologics designed to block the LAG-3/MHCII interaction.
TCR Activating Antigen (Cat.# K1201) is an antigen that is presented by MHCII on MHCII APC Cells to specifically activate the TCR on the LAG-3 Effector Cells, designed for use with the LAG-3/MHCII Blockade Bioassay.